Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karen Krasney Insider Profile
4 Followers
Karen Krasney, EVP & GC at Capricor Therapeutics, holds 20.05K shares in Capricor Therapeutics (Ticker: CAPR). Most recently, Karen Krasney Bought $18,932 shares of Capricor Therapeutics on Nov 04, 2022 for an estimated value of 26.32K.
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
-19.10%
Average return per transaction
Time Frame
Compare to
Insider Roles
EVP & GC
Roles that Karen Krasney holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 18, 2016 - Mar 18, 2017
Return:+26.90%
The most profitable trade made by Karen Krasney
Karen Krasney's Trading History
List of latest transactions for each holding click on a transaction to see Karen Krasney's performance on stock
You May Also Like
Karen Krasney insider profile FAQ
What is the percentage of profitable transactions made by Karen Krasney?
The percentage of profitable transactions made by Karen Krasney is 33%.
What is the average return per transaction made by Karen Krasney?
The average return per transaction made by Karen Krasney is -19.10%.
What stocks does Karen Krasney hold?
Karen Krasney holds: CAPR stocks.
What was Karen Krasney’s latest transaction?
Karen Krasney latest transaction was an Informative Buy of $26.32K.
What was Karen Krasney's most profitable transaction?
Karen Krasney’s most profitable transaction was an Informative Buy of CAPR stock on March 18, 2016. The return on the trade was 26.90%.
What is Karen Krasney's role in Capricor Therapeutics?
Karen Krasney's role in Capricor Therapeutics is EVP & GC.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.